RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR ...

(RTTNews) - Compass Pathways plc (CMPS) announced Monday that its investigational psilocybin therapy, COMP360, met the primary endpoint in the Phase 3 COMP005 trial for treatment-resistant ...

ACHIEVE-1 is a phase 3 trial, which evaluated the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.

Add a description, image, and links to the 3-phase-inverter topic page so that developers can more easily learn about it. Curate this topic Add this topic to your repo To associate your repository ...

Candidates can complete the registrations for phase 3 through the official website- dost.cgg.gov.in. As per the schedule, the deadline to apply for the TSCHE DOST 2025 admission through web options is ...

Second ongoing pivotal Phase 3 COMP006 trial continues to enroll well, with 26-week data expected in the second half of 2026; LONDON & NEW YORK--(BUSINESS WIRE) ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday.. A total of 106 patients with ...

Terra AC wallbox type 2, socket, 3-phase/32 A, MID certified, with RFID and display Product details SKU Code: 6AGC081280 EAN Code: 8719874450973 Minimum order: 8 Add to Cart Available for Back Order ...

Phase II trials are conducted to provide evidence of the effectiveness of a therapeutic intervention in patients and to determine the optimal treatment regimen (for example, dosing schedule) for ...

INDIANAPOLIS, June 21, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron ...